Department of Breast Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.
Department of Pathology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.
Anticancer Res. 2020 Jun;40(6):3315-3323. doi: 10.21873/anticanres.14314.
BACKGROUND/AIM: To evaluate the improvement in the prognosis by adjuvant trastuzumab in clinical practice and the risk factors for distant recurrence, we retrospectively investigated the prognosis of HER2-positive early breast cancer in our department before and after the introduction of adjuvant trastuzumab.
Cohorts A and B included 161 and 182 cases, respectively, who underwent surgery before (2000-2007) and after (2008-2015) the introduction of adjuvant trastuzumab.
The rates of relapse-free and distant metastasis-free survival were significantly better in cohort B than in cohort A. The risk factors of distant recurrence found in cohort A, such as the presence of lymph node metastasis, lymphatic invasion, and a low histological grade, did not increase the risk in cohort B.
Many risk factors seemed to have been negated by adjuvant trastuzumab administration. Therefore, further escalation of adjuvant treatment should be carefully considered.
背景/目的：评估曲妥珠单抗辅助治疗在临床实践中的预后改善情况以及远处复发的危险因素，我们回顾性研究了曲妥珠单抗辅助治疗引入前后本部门 HER2 阳性早期乳腺癌的预后。
队列 A 和队列 B 分别纳入了 161 例和 182 例患者，分别接受了曲妥珠单抗辅助治疗引入前（2000-2007 年）和引入后（2008-2015 年）的手术治疗。
队列 B 的无复发生存率和无远处转移生存率明显优于队列 A。队列 A 中发现的远处复发的危险因素，如淋巴结转移、淋巴管浸润和低组织学分级，在队列 B 中并未增加风险。
许多危险因素似乎被曲妥珠单抗辅助治疗所消除。因此，应慎重考虑进一步强化辅助治疗。
